Results 91 to 100 of about 11,904 (210)

Blonanserin transdermal patch for treating delirium: A case series

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
In a retrospective case series of 51 patients with delirium treated at a single center between 2020 and 2022, clinical improvement was observed in 84.3% of patients following the use of a blonanserin transdermal patch, often within 1–2 weeks. The patch was mainly selected for patients who had difficulty taking oral medications.
Mari Hemmi, Takuma Yamaguchi, Yuki Shigetsura, Daiki Hira, Hitoshi Tanimukai, Hirotsugu Kawashima, Yukiko Miyoshi, Hiroki Endo, Shunsaku Nakagawa, Tomohiro Terada   +9 more
wiley   +1 more source

Bioavailability file: Rivastigmine tartrate

, 2005
Rivastigmine tartrate is a carbamate derivative drug used for treatment of mild to moderate Alzheimer's disease. It is used for increasing cognitive performance aiming to continue the patient's daily life.
Deǧim, Zelihagül, Mutlu, NECİBE BAŞARAN   +1 more
core  

The Associations Between Dietary Flavonoid Intake and Neurodegenerative Diseases Risk: A Cross‐Sectional Study

Chemical Biology &Drug Design, Volume 107, Issue 6, June 2026.
Total flavonoid intake was significantly inversely associated with neurodegenerative diseases risk. Participants in the highest quartile (Q4) of total flavonoid intake exhibited a 48% lower risk compared to those in the lowest quartile (Q1) (OR = 0.52, 95% CI: 0.31–0.90; p for trend = 0.016).
Chenzhong Zong, Yang Dong, Xue Yu, Yu He, Xiaoqing Zhang, Kuo Gao   +5 more
wiley   +1 more source

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis

, 2008
Richard A Hansen1, Gerald Gartlehner2, Aaron P Webb1, Laura C Morgan3, Charity G Moore4, Daniel E Jonas31School of Pharmacy, 3Cecil G Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC, USA; 2Department for Evidence ...
Daniel E Jonas, Aaron P Webb, Laura C Morgan, Richard A Hansen, Gerald Gartlehner, Charity G Moore   +5 more
core  

Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients

, 2008
The effects of rivastigmine versus placebo in Parkinson's disease dementia (PDD) patients with elevated or normal/low plasma. homocysteine were determined.
Werner Poewe, Poewe, Werner, Roger M. Lane, Hsu, Chuanchieh, Burn, David J., van Laar, Teus, David J. Burn, Paolo Barone, Chuanchieh Hsu, Teus van Laar, Barone, Paolo, Lane, Roger M.   +11 more
core   +1 more source

Dementia Risk in Type 1 and 2 Diabetes: A Nationwide Population‐Based Comparison

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4915-4925, June 2026.
ABSTRACT Aims Diabetes is increasingly recognised as a major contributor to cognitive decline and dementia, but the risk varies by diabetes type and treatment intensity. We compared the risk of all‐cause dementia, Alzheimer's disease (AD) and vascular dementia (VaD) among individuals with and without diabetes.
Ji Eun Jun, Seohyun Kim, In‐Kyung Jeong, Jae Hyeon Kim   +3 more
wiley   +1 more source

Impact of Rivastigmine Patch and Capsules on Activities of Daily Living in Alzheimer’s Disease

, 2011
Background: Rivastigmine patches provide similar efficacy to rivastigmine capsules with a lower incidence of gastrointestinal side effects in patients with probable Alzheimer’s disease (AD).
null Xiangyi Meng, George Grossberg, Jason T. Olin   +2 more
core   +1 more source

Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits [PDF]

, 2017
Rivastigmine has been shown to improve cognition in HIV+ patients with minor neurocognitive disorders; however, the mechanisms underlying such beneficial effect are currently unknown.
David Romascano, Reto Meuli, Renaud A. Du Pasquier, Meuli, R., Meuli, Reto, Aydarkhanov, Ruslan, Meskaldji, Djalel-Eddine, Melanie Metral, Cavassini, M., Du Pasquier, Renaud A, Daducci, Alessandro, Daducci, A., Krueger, Gunnar, Lazeyras, François, Du Pasquier, Renaud A., Romascano, David, Alessandro Daducci, Meskaldji, Djalel‐Eddine, Djalel-Eddine Meskaldji, Perrotta, G., Bonnier, G., François Lazeyras, Aydarkhanov, R., Metral, M., Gaetano Perrotta, Granziera, C., Simioni, Samanta, Ruslan Aydarkhanov, Simioni, S., Lazeyras, F., Krueger, G., Gunnar Krueger, Bonnier, Guillaume, Meskaldji, D.E., Perrotta, Gaetano, Guillaume Bonnier, Cristina Granziera, Du Pasquier, R.A., Metral, Melanie, Samanta Simioni, Romascano, D., Granziera, Cristina, Cavassini, Matthias, Matthias Cavassini   +43 more
core   +1 more source

Neurotransmitter Systems Underlying Freezing of Gait (FOG) in Parkinson's Disease

European Journal of Neuroscience, Volume 63, Issue 12, June 2026.
Freezing of gait (FOG) in Parkinson's disease (PD) arises from dysfunction across multiple neurotransmitter systems within distributed locomotor networks. While dopaminergic deficits contribute to levodopa‐responsive FOG, nondopaminergic systems including cholinergic, noradrenergic, serotonergic, and glutamatergic/GABAergic pathways play key roles in ...
Minsub Cho, Jin Whan Cho, Dallah Yoo, Jinse Park, Do‐Young Kwon, Seong‐Beom Koh, Jeong‐Ho Park, Jinyoung Youn   +7 more
wiley   +1 more source

Rivastigmine in Alzheimer’s Disease and Parkinson’s Disease Dementia

, 2011
Rivastigmine treatment is associated with significant improvements on the cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog) in patients with mild-to-moderate Alzheimer’s disease (AD) and Parkinson’s disease dementia (PDD).
Xiangyi Meng, Monique Somogyi, Daniel Weintraub   +2 more
core   +1 more source